Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahvash, Armeen, Murthy, Ravi, Odisio, Bruno C, Raghav, Kanwal Pratap, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Ensor, Joe, Gadani, Sameer, Elsayes, Khaled M, Abdel-Wahab, Reham, Hassan, Manal, Shalaby, Ahmed S, Yao, James C, Wallace, Michael J, Kaseb, Ahmed O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994795/
https://www.ncbi.nlm.nih.gov/pubmed/27574586
http://dx.doi.org/10.2147/JHC.S62261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994795/
https://www.ncbi.nlm.nih.gov/pubmed/27574586
http://dx.doi.org/10.2147/JHC.S62261

Ejemplares similares